These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 37718851)

  • 1. Incretin Mimetics Restore the ER-Mitochondrial Axis and Switch Cell Fate Towards Survival in LUHMES Dopaminergic-Like Neurons: Implications for Novel Therapeutic Strategies in Parkinson's Disease.
    Panagaki T; Randi EB; Szabo C; Hölscher C
    J Parkinsons Dis; 2023; 13(7):1149-1174. PubMed ID: 37718851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH-SY5Y cells.
    Jalewa J; Sharma MK; Hölscher C
    J Neurochem; 2016 Oct; 139(1):55-67. PubMed ID: 27412483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The novel GLP-1/GIP dual agonist DA3-CH is more effective than liraglutide in reducing endoplasmic reticulum stress in diabetic rats with cerebral ischemia-reperfusion injury.
    Bai B; Li D; Xue G; Feng P; Wang M; Han Y; Wang Y; Hölscher C
    Nutr Metab Cardiovasc Dis; 2021 Jan; 31(1):333-343. PubMed ID: 33500109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease.
    Yuan Z; Li D; Feng P; Xue G; Ji C; Li G; Hölscher C
    Eur J Pharmacol; 2017 Oct; 812():82-90. PubMed ID: 28666800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson's Disease.
    Zhang L; Zhang L; Li Y; Li L; Melchiorsen JU; Rosenkilde M; Hölscher C
    J Parkinsons Dis; 2020; 10(2):523-542. PubMed ID: 31958096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Novel DA-CH3 Dual Incretin Restores Endoplasmic Reticulum Stress and Autophagy Impairments to Attenuate Alzheimer-Like Pathology and Cognitive Decrements in the APPSWE/PS1ΔE9 Mouse Model.
    Panagaki T; Gengler S; Hölscher C
    J Alzheimers Dis; 2018; 66(1):195-218. PubMed ID: 30282365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease.
    Salles GN; Calió ML; Hölscher C; Pacheco-Soares C; Porcionatto M; Lobo AO
    Neuropharmacology; 2020 Jan; 162():107813. PubMed ID: 31628935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Dual GLP-1/GIP Receptor Agonist Is More Effective than Liraglutide in the A53T Mouse Model of Parkinson's Disease.
    Zhang Z; Shi M; Li Z; Ling Y; Zhai L; Yuan Y; Ma H; Hao L; Li Z; Zhang Z; Hölscher C
    Parkinsons Dis; 2023; 2023():7427136. PubMed ID: 37791037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives.
    Ferrari F; Moretti A; Villa RF
    Pharmacol Ther; 2022 Nov; 239():108277. PubMed ID: 36064147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysregulation of the Mitochondrial Unfolded Protein Response Induces Non-Apoptotic Dopaminergic Neurodegeneration in
    Martinez BA; Petersen DA; Gaeta AL; Stanley SP; Caldwell GA; Caldwell KA
    J Neurosci; 2017 Nov; 37(46):11085-11100. PubMed ID: 29030433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics.
    Salameh TS; Rhea EM; Talbot K; Banks WA
    Biochem Pharmacol; 2020 Oct; 180():114187. PubMed ID: 32755557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A GLP-2 Analogue Protects SH-SY5Y and Neuro-2a Cells Against Mitochondrial Damage, Autophagy Impairments and Apoptosis in a Parkinson Model.
    Su Y; Zhang Z; Li H; Ma J; Sun L; Shao S; Zhang Z; Hölscher C
    Drug Res (Stuttg); 2021 Jan; 71(1):43-50. PubMed ID: 33022720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liraglutide Regulates Mitochondrial Quality Control System Through PGC-1α in a Mouse Model of Parkinson's Disease.
    Wu P; Dong Y; Chen J; Guan T; Cao B; Zhang Y; Qi Y; Guan Z; Wang Y
    Neurotox Res; 2022 Feb; 40(1):286-297. PubMed ID: 35043376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease.
    Nowell J; Blunt E; Gupta D; Edison P
    Ageing Res Rev; 2023 Aug; 89():101979. PubMed ID: 37328112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GIP has neuroprotective effects in Alzheimer and Parkinson's disease models.
    Zhang ZQ; Hölscher C
    Peptides; 2020 Mar; 125():170184. PubMed ID: 31705913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deficiency of RAB39B Activates ER Stress-Induced Pro-apoptotic Pathway and Causes Mitochondrial Dysfunction and Oxidative Stress in Dopaminergic Neurons by Impairing Autophagy and Upregulating α-Synuclein.
    Chiu CC; Weng YH; Yeh TH; Lu JC; Chen WS; Li AH; Chen YL; Wei KC; Wang HL
    Mol Neurobiol; 2023 May; 60(5):2706-2728. PubMed ID: 36715921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endoplasmic Reticulum Stress Regulators: New Drug Targets for Parkinson's Disease.
    Kovaleva V; Saarma M
    J Parkinsons Dis; 2021; 11(s2):S219-S228. PubMed ID: 34180421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liraglutide restores chronic ER stress, autophagy impairments and apoptotic signalling in SH-SY5Y cells.
    Panagaki T; Michael M; Hölscher C
    Sci Rep; 2017 Nov; 7(1):16158. PubMed ID: 29170452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Geraniol Protects Against the Protein and Oxidative Stress Induced by Rotenone in an In Vitro Model of Parkinson's Disease.
    Rekha KR; Inmozhi Sivakamasundari R
    Neurochem Res; 2018 Oct; 43(10):1947-1962. PubMed ID: 30141137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson's disease.
    Yang X; Feng P; Ji R; Ren Y; Wei W; Hölscher C
    Expert Opin Ther Targets; 2022 May; 26(5):445-460. PubMed ID: 35584372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.